According to the latest report published by Credence Research, Inc. “Hypercalcemia Treatment Market – Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global hypercalcemia treatment market was valued at US$ 9,544.1 Mn in 2017 and expected to reach US$ 23,707.8 Mn by 2026, expanding at a CAGR of 10.7% from 2018 to 2026.
[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]
The global market for hypercalcemia care is projected to reach US$ 23,707.8 million by 2026 from US$ 9,544.1 million in 2017, rising at CAGR by 10.7 per cent during the 2018 to 2026 forecast period. Hypercalcemia is a metabolic disorder caused by elevated calcium levels, with serum calcium levels exceeding 2.6 mmol / L. Hypercalcemia is generally the result of overactive parathyroid glands and may occur in cancer patients, primarily in patients with lung and breast cancer. Other factors contributing to the development of disorder include hereditary factors, severe dehydration, medications, and supplements. Patients are prescribed therapeutic calcium regulation.
Based on the drug class, the global market for treatment with hypercalcemia is divided into bisphosphonates, calcitonin, glucocorticoids, calcimimetic agents and denusomab. Bisphosphonates are further sub-segmented into clodronate, etidronate, ibandronate, pamidronate and zoledronic acid. In 2017, the bisphosphonate product dominated the global market for the treatment of hypercalcemia due to a growing demand for the treatment of the disease. Other drug classes, including glucocorticoids and calcimetic agents, are expected to grow steadily during the forecast period. As generics dominate the market, the label extension of drugs for the treatment of more indications is also expected to contribute to the growth of the market.
On the basis of geographical demarcation, North America America and Europe together contributed more than 63% of the global market share for hypercalcemia treatment in 2017, with North America at the lead. High prevalence of malignancy-related hypercalcemia and increased disease understanding in both regions are key factors for dominance. The Asia-Pacific and Latin America hypercalcemia treatment markets are expected to see the fastest growth in double digit CAGR during the forecast period due to increased healthcare spending and increased awareness of hypercalcemia.
The global hypercalcemia treatment market is highly fragmented due to the presence of numerous local and international market players. Since most of the therapeutics are generic, several players are manufacturing the drugs and competing in the global market. Further, some of the players are investing in research & development for hypercalcemia to capture the prominent market share. Key players in the market include Amgen, Inc., Bayer Pharma AG, Mylan N.V., Pfizer Inc., Cipla, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, and Dr. Reddy’s Laboratories Ltd.